Literature DB >> 7523722

Natural history of changes in prostate specific antigen in early stage prostate cancer.

J D Pearson1, H B Carter.   

Abstract

Until recently, the only information on the growth rate of prostate tumors has been derived from cross-sectional histological labeling studies, autopsy data and clinical studies of patients managed expectantly. However, serial measurements of prostate specific antigen (PSA) may now allow studies of the natural history of the earliest stages of prostate cancer. Frozen sera samples from the Baltimore Longitudinal Study of Aging have been used to compare the patterns of change in PSA levels in men with and without prostate cancer up to 25 years before the diagnosis of cancer. Men with no prostatic disease exhibited a slow linear increase in PSA levels, whereas benign prostatic hyperplasia cases showed a gradual acceleration in the rate of change in PSA. In contrast, cancer cases exhibited an early linear phase followed by an exponential phase of increase in PSA levels before diagnosis. On average, the exponential phase of PSA increases began 7 to 9 years before the tumors were detected clinically. Thus, there is a significant window of opportunity for early detection of prostate cancer. The changes in PSA observed in men with and without prostate cancer are consistent with available information on prostatic growth and the long natural history of prostate cancer. A better understanding of the various factors that affect serum PSA levels may allow more effective use of PSA measurements to detect early stage tumors and predict the biological potential of a tumor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523722     DOI: 10.1016/s0022-5347(17)32375-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.

Authors:  Andre C King; Andrew Livermore; Timo A J Laurila; Wei Huang; David F Jarrard
Journal:  Urol Oncol       Date:  2011-08-03       Impact factor: 3.498

2.  Screening for prostate cancer: estimating the magnitude of overdetection.

Authors:  M McGregor; J A Hanley; J F Boivin; R G McLean
Journal:  CMAJ       Date:  1998-12-01       Impact factor: 8.262

3.  Age-specific PSA reference ranges in a group of non-urologic patients.

Authors:  A C Atalay; M I Karaman; S Güney; A Dalkiliç; A Y Müslümanoğlu; E Ergenekon
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

4.  Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study.

Authors:  Steven J Jacobsen; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; George G Klee; Cynthia J Girman; Michael M Lieber
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 5.  Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes.

Authors:  Yoshiyuki Kakehi
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

6.  Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.

Authors:  Caroline J Savage; Hans Lilja; Angel M Cronin; David Ulmert; Andrew J Vickers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-04-20       Impact factor: 4.254

7.  Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years.

Authors:  Maria Chiara Sighinolfi; Salvatore Micali; Stefano De Stefani; Arrigo Cicero; Filippo Cianci; Marco Giacometti; Giampaolo Bianchi
Journal:  Asian J Androl       Date:  2009-05-18       Impact factor: 3.285

8.  Prostate-specific antigen density--a reliable parameter for the detection of prostate cancer?

Authors:  W F Thon; F Gadban; M C Truss; M Kuczyk; U Hartmann; U Jonas
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 9.  Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.

Authors:  Richard M Martin; David Gunnell; Freddie Hamdy; David Neal; Athene Lane; Jenny Donovan
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

Review 10.  The role of prostate-specific antigen velocity in prostate cancer early detection.

Authors:  S R Potter; H B Carter
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.